Hospice By The Sea Medicare Approved Location: 312 S Cedros, Suite 250, Solana Beach, California 92075 Phone: (858) 794-0195 |
News Archive
A study suggests it may be possible to identify those who will not benefit from drug combination for advanced ovarian cancer.
Stryker Orthopaedics today announced the release of the ADM X3 Mobile Bearing Acetabular System, a next-generation technology for hip replacement surgery designed to minimize the risks associated with total hip replacement surgery.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with AvastinĀ® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.
Hospitals in the Atlanta area vary in terms of how well their intensive care units (ICUs) prevent central-line bloodstream infections, a cause of death, disability, and expense in our nations' hospitals that is largely preventable. On February 2, www.ConsumerReportsHealth.org will post hospital infection rates for 12 Atlanta area hospitals that voluntarily reported their infection rates.
Manchester Pharmaceuticals, Inc.(TM) announced today the availability of Chenodal(TM) 250 mg (chenodiol tablets). On October 22, 2009, the US Food and Drug Administration (FDA) approved Chenodal, an important therapy for patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.
› Verified 3 days ago